Enanta Pharmaceuticals, Inc.

ENTA

NASDAQ

Healthcare

Biotechnology

Watertown, MA, US131 employeesenanta.com

$13.15

+0.18(1.39%)

Mkt Cap $305M

$4.26

$16.85

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Royalty (99.5%), License (0.5%).

8-K

Enanta Pharmaceuticals, Inc. disclosed that on March 20, 2026, the United States Court of Appeals for the Federal Circuit scheduled oral argument for May 11, 2026, in the Company's appeal filed on February 3, 2025, against Pfizer Inc. for infringement of U.S. Patent No. 11,358,953 related to Paxlovid™.

$305M

Market Cap

$73M

Revenue

-$78M

Net Income

Employees131

Fundamentals

How The Business Makes Money

Revenue by Segment

Royalty99.5%($211M)

License0.5%($1M)

Activity

What Changed Recently

Management Change

Mar 11, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed

Financial Results

Feb 8, 2026

Results of Operations and Financial Condition. On February 9, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter

Other Event

Mar 25, 2026

Other Events. As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), on February 3, 2025, the Company filed a notice of appeal with the United

Peer Companies

Company	Price	Change	Market Cap	P/E
ASMBAssembly Biosciences, Inc...	$29.09	-1.17%	$461M	-52.3
AVIRAtea Pharmaceuticals, Inc...	$5.75	+1.86%	$459M	-2.7
NAUTNautilus Biotechnology, I...	$3.31	-1.49%	$418M	-7.7
FHTXFoghorn Therapeutics Inc.	$4.93	+0.61%	$289M	-4.3
VYGRVoyager Therapeutics, Inc...	$3.94	-1.13%	$235M	-1.9
IMRXImmuneering Corporation	$5.45	+2.25%	$198M	-4.0
PRLDPrelude Therapeutics Inco...	$3.51	+1.74%	$196M	-2.0
CRBUCaribou Biosciences, Inc.	$1.94	-2.76%	$187M	-1.2

Analyst View

Company Profile

CIK0001177648

ISINUS29251M1062

CUSIP29251M106

Phone617 607 0800

Address500 Arsenal Street, Watertown, MA, 02472, US

SEC EDGAR